APM News and Press, Aptorum Group Limited From 05/22/19

Aptorum Group Limited (Nasdaq: APM) (“the Company”) a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today the Company’s addition to the Morgan Stanley C...

Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group Ltd (Nasdaq: APM), is launching its flagship fund - Pyrinas US Healthcare Real Estate Fund 1 SP – to acquire and develop co-working space and incubator facilities for the life sciences sector in the United States...

Claves Life Sciences Limited, a wholly owned subsidiary of Aptorum Group Limited ("Aptorum") (Nasdaq: APM), is excited to announce the establishment of a novel therapeutic platform for the treatment of various diseases via modulation of the chemical signaling relating to gut microbiota. The ...

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on Aptorum Group Limited (NasdaqGM: APM) Click  here  to view Full Argus Report Highlights, as conveyed by Argus Analyst Stev...

Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$90 million agreement to co-create local deep tech start-ups in the healthcare and life scien...

Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“ SMPT ”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“ SPLP ”) targeted in May 201...

Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACT TM ”...

Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-n...

Aptorum Group Limited (NASDAQ: APM ): FY GAAP EPS of -$0.53. More news on: Aptorum Group Limited, Earnings news and commentary, Read more ...

Aptorum Group Ltd. (NASDAQ: APM), a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs, today provided a business update and announced financial resul...